catwalk-logocatwalk-logocatwalk-logocatwalk-logo
  • Research
    • Funded Projects
    • The Spinal Cord Injury Research Facility
    • Latest Research
    • Grant applications
  • Help us
    • Donate
    • Upcoming Events
    • Leaving a gift in your Will
    • Support Us
    • Get Involved
  • Events
    • The Tora!
    • Grocery Charity Ball
    • CatWalk Golf Open
    • Queenstown Marathon – 19th Nov 2022
    • DigDeep4CatWalk
    • Pot of Gold Raffle
  • News
    • Latest News
    • CatWalk Magazine
    • Subscribe to our magazine
  • About
    • Supporters
    • Our Network
    • Board of Trustees
    • Founder
    • Terms of Website Use
    • Donations Refund Policy
    • Privacy Policy
    • Terms and Conditions of Supply
    • Returns Policy for Online Orders
  • Contact
  • Donate Now
0

$0.00

✕

CatWalk funding supports an international trial

  • Home
  • News
  • News & Events
  • Latest Research
  • CatWalk funding supports an international trial

The Riluzole in Acute Spinal Cord Injury Study (RISCIS): A multi-centre, placebo-controlled, randomized trial of the safety and efficacy of riluzole as a neuroprotective agent for acute traumatic SCI.

 

Host institution University Health Network, Toronto, Ontario, Canada
Research locations Middlemore Hospital, Otahuhu, Auckland and Christchurch Hospital,
Christchurch, New Zealand
Lead investigator Michael G. Fehlings, MD PhD FRCSC FACS
Funding amount $299,400
Funding term 1 January 2019 – 31 December 2021

 

CatWalk is providing funding to support the inclusion of two New Zealand hospitals in a major international SCI clinical drug trial.
Funding will be used to add Middlemore Hospital in Auckland and the Burwood Spinal Unit in Christchurch to a large-scale trial, which is already running consecutively in 23 hospitals around the world.

An initial insult to the spinal cord triggers mechanisms that create further injury. There is strong data that the drug Riluzole lessens secondary impact in SCI and leads to reduced neurological tissue destruction and improved function. The aim of this randomized trial is to evaluate the safety and effectiveness of Riluzole in the treatment of patients with traumatic SCI.

The clinical trial will monitor the success of the drug in treatments, based on earlier clinical data which suggests that the drug has the potential to improve motor sensory functionality for those living with SCI.

Expanding the trial to Kiwi hospitals will help to boost patient recruitment for the study, meaning the success of the drug could be demonstrated up to a year earlier than forecast. This means a treatment resulting in improved outcomes for those living with SCI could be made available a year earlier.

The results of this trial have the potential to change clinical practice, and may mitigate the burden of disability on SCI patients, families, and society.

The trial is led globally by Professor Michael Fehlings, a neurosurgeon based at Toronto Western Hospital in Canada. Prof. Fehlings is internationally regarded as a leader in SCI clinical trials around the globe,
and expanding his trial to New Zealand is something of a coup for our local researchers and medical professionals.

CatWalk is committed to supporting world-class SCI research and innovation. On top of the leading research we support here in New Zealand, we are extremely proud to be able to facilitate local involvement in an international research project of such magnitude.

Related posts

March 16, 2022

Bio Spine Clinical Trial – Australian based participants required


Read more
March 15, 2022

Trial Participants Required in New Zealand


Read more
March 4, 2022

The 2022 Brain Prize has been awarded to a former Hamiltonian for his pioneering spinal cord research


Read more

About Us

Returns Policy for Online Orders


Terms and Conditions of Supply


Donation Refund


Terms of Website Use


Privacy Policy.

The Catwalk Spinal
Cord Injury Trust
T/A The CatWalk Trust

PO Box 555,
Masterton 5840,
New Zealand

06 377 5430

info@catwalk.org.nz

CatWalkTrust

@thecatwalktrust

@catwalk_trust

CatWalk Trust

Subscribe to our newsletter

SIGN ME UP

@ The CatWalk Spinal Cord Injury Trust is registered in New Zealand under the Charities Act 2005 CC27170.
Trading as The CatWalk Spinal Cord Injury Research Trust & The CatWalk Trust.
Website design Mirage Visual
    0

    $0.00

      ✕

      Login

      Lost your password?